Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuo Nagano

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|October 22, 2003
[Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients]Nobuo Nagano, Naoshi Fukushima
Clinical Calcium|May 28, 2016
[Pharmacological characteristics of drugs targeted on calcium-sensing receptor.-properties of cinacalcet hydrochloride as allosteric modulator]Nobuo Nagano, Takaaki Tsutsui
Journal of Pharmacological Sciences|March 23, 2005
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimeticsNobuo Nagano, Edward F Nemeth
Nephron. Clinical Practice|November 18, 2014
Fibroblast growth factor 23/klotho axis in chronic kidney diseaseKosaku Nitta, Nobuo Nagano, Ken Tsuchiya
American Journal of Physiology. Endocrinology and Metabolism|June 5, 2012
Pathogenesis of secondary hyperparathyroidism and fibroblast growth factor 23: a pharmacological validation of the "trade-off hypothesis"Nobuo Nagano, Tetsuo Ando, Yohnosuke Shimomura
Contributions to Nephrology|May 30, 2015
Klotho/FGF23 Axis in CKDKen Tsuchiya, Nobuo Nagano, Kosaku Nitta
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|November 15, 2008
[Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)]Nobuo Nagano, Takehisa Kawata, Michihito Wada
Clinical Calcium|October 2, 2012
[Cinacalcet hydrochloride and phosphate metabolism]Nobuo Nagano, Tetsuo Ando, Kyoko Ito, et al.
Clinical and Experimental Nephrology|October 31, 2025
Association between serum hepcidin-25 levels and hyporesponsiveness to erythropoiesis-stimulating agents in Japanese patients receiving hemodialysis: a cross-sectional studyRyo Fujikawa, Nobuo Nagano, Yuko Mitobe, et al.
NDT Plus|June 29, 2017
The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate: when should cinacalcet hydrochloride be administered?Toshiyuki Date, Yoshiteru Kawashita, Mika Matsuzaki, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|October 22, 2003
[Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients]Nobuo Nagano, Naoshi Fukushima
Clinical Calcium|May 28, 2016
[Pharmacological characteristics of drugs targeted on calcium-sensing receptor.-properties of cinacalcet hydrochloride as allosteric modulator]Nobuo Nagano, Takaaki Tsutsui
Journal of Pharmacological Sciences|March 23, 2005
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimeticsNobuo Nagano, Edward F Nemeth
Nephron. Clinical Practice|November 18, 2014
Fibroblast growth factor 23/klotho axis in chronic kidney diseaseKosaku Nitta, Nobuo Nagano, Ken Tsuchiya
American Journal of Physiology. Endocrinology and Metabolism|June 5, 2012
Pathogenesis of secondary hyperparathyroidism and fibroblast growth factor 23: a pharmacological validation of the "trade-off hypothesis"Nobuo Nagano, Tetsuo Ando, Yohnosuke Shimomura
Contributions to Nephrology|May 30, 2015
Klotho/FGF23 Axis in CKDKen Tsuchiya, Nobuo Nagano, Kosaku Nitta
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|November 15, 2008
[Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)]Nobuo Nagano, Takehisa Kawata, Michihito Wada
Clinical Calcium|October 2, 2012
[Cinacalcet hydrochloride and phosphate metabolism]Nobuo Nagano, Tetsuo Ando, Kyoko Ito, et al.
Clinical and Experimental Nephrology|October 31, 2025
Association between serum hepcidin-25 levels and hyporesponsiveness to erythropoiesis-stimulating agents in Japanese patients receiving hemodialysis: a cross-sectional studyRyo Fujikawa, Nobuo Nagano, Yuko Mitobe, et al.
NDT Plus|June 29, 2017
The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate: when should cinacalcet hydrochloride be administered?Toshiyuki Date, Yoshiteru Kawashita, Mika Matsuzaki, et al.
Pageof 5